Showing results (71-80 of 86) with videos related to
Sort By:
Pageof 9
Ebiomedicine|November 2, 2024
Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection caseTakeo Kuwata, Yu Kaku, Shashwata Biswas, et al.Plos Pathogens|August 12, 2010
Biological and structural characterization of a host-adapting amino acid in influenza virusShinya Yamada, Masato Hatta, Bart L Staker, et al.Iscience|November 21, 2022
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal modelsMasaru Takeshita, Hidehiro Fukuyama, Katsuhiko Kamada, et al.Proceedings of the National Academy of Sciences of the United States of America|June 24, 2020
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure developmentMasaki Imai, Kiyoko Iwatsuki-Horimoto, Masato Hatta, et al.Eclinicalmedicine|February 16, 2021
Antibody titers against SARS-CoV-2 decline, but do not disappear for several monthsSeiya Yamayoshi, Atsuhiro Yasuhara, Mutsumi Ito, et al.Cell Host & Microbe|October 24, 2017
A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory DropletsMasaki Imai, Tokiko Watanabe, Maki Kiso, et al.Nature Microbiology|August 31, 2016
Selection of antigenically advanced variants of seasonal influenza virusesChengjun Li, Masato Hatta, David F Burke, et al.Journal of Virology|September 23, 2011
Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaquesTokiko Watanabe, Kyoko Shinya, Shinji Watanabe, et al.Nature|November 25, 2021
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutationAkatsuki Saito, Takashi Irie, Rigel Suzuki, et al.Research Square|March 2, 2022
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2Yoshihiro Kawaoka, Ryuta Uraki, Maki Kiso, et al.Pageof 9